Amina Zoubeidi
#178,841
Most Influential Person Now
Canadian research scientist and urologist
Amina Zoubeidi's AcademicInfluence.com Rankings
Amina Zoubeidiengineering Degrees
Engineering
#8415
World Rank
#9950
Historical Rank
Biomedical Engineering
#855
World Rank
#868
Historical Rank
Amina Zoubeidiphilosophy Degrees
Philosophy
#11304
World Rank
#15555
Historical Rank
Logic
#8117
World Rank
#10106
Historical Rank
Download Badge
Engineering Philosophy
Why Is Amina Zoubeidi Influential?
(Suggest an Edit or Addition)According to Wikipedia, Amina Zoubeidi is a Canadian research scientist and prostate cancer researcher. She's a scientist at the Vancouver Coastal Health Research Institute and an associate professor in the Department of Urologic Sciences at the University of British Columbia. During her tenure at UBC, Zoubeidi and her research team developed the first drug that targets and blocks BRN2, thus stopping Neuroendocrine prostate cancer tumours and creating a possible treatment for the previously thought incurable disease.
Amina Zoubeidi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
- Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. (2007) (241)
- The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. (2017) (236)
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer (2014) (224)
- Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19 (2018) (219)
- Cellular plasticity and the neuroendocrine phenotype in prostate cancer (2018) (218)
- The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. (2015) (203)
- Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. (2013) (185)
- From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer (2012) (173)
- Small heat shock proteins in cancer therapy and prognosis. (2012) (160)
- The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance (2019) (149)
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer (2010) (143)
- Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. (2012) (136)
- Clusterin knockdown using the antisense oligonucleotide OGX‐011 re‐sensitizes docetaxel‐refractory prostate cancer PC‐3 cells to chemotherapy (2008) (127)
- Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). (2014) (124)
- ONECUT2 is a driver of neuroendocrine prostate cancer (2019) (121)
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo (2013) (120)
- The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer (2014) (114)
- Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells (2010) (113)
- A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo (2013) (108)
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth (2015) (108)
- Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. (2018) (103)
- Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival (2014) (102)
- DNA methylation landscapes in advanced prostate cancer (2020) (98)
- GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer (2013) (97)
- Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. (2015) (93)
- MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. (2017) (93)
- Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363 (2012) (93)
- A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer (2017) (90)
- Clusterin as a therapeutic target (2017) (90)
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer (2014) (87)
- Targeting heat shock proteins in metastatic castration-resistant prostate cancer (2015) (87)
- Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. (2010) (87)
- The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management. (2019) (78)
- Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. (2011) (77)
- Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. (2014) (75)
- Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer (2011) (69)
- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 (2020) (66)
- Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo (2011) (63)
- Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. (2013) (62)
- Hsp27 regulates EGF/β‐catenin mediated epithelial to mesenchymal transition in prostate cancer (2015) (60)
- LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. (2017) (59)
- Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. (2014) (58)
- Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance (2010) (57)
- A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis (2011) (57)
- Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer (2012) (56)
- Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts (2015) (56)
- Links between Fer tyrosine kinase expression levels and prostate cell proliferation (2000) (55)
- Biological Evolution of Castration-resistant Prostate Cancer. (2019) (53)
- Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. (2011) (49)
- Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch (2011) (49)
- Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
- Intravesically administered antisense oligonucleotides targeting heat‐shock protein‐27 inhibit the growth of non‐muscle‐invasive bladder cancer (2008) (47)
- Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer (2019) (46)
- The Fer Tyrosine Kinase Cooperates with Interleukin-6 to Activate Signal Transducer and Activator of Transcription 3 and Promote Human Prostate Cancer Cell Growth (2009) (46)
- The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications (2018) (46)
- Hsp27 Inhibition with OGX-427 Sensitizes Non–Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy (2015) (46)
- Dual inhibition of autophagy and the AKT pathway in prostate cancer (2013) (44)
- The DNA methylation landscape of advanced prostate cancer (2020) (44)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer (2008) (44)
- Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. (2015) (43)
- TAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domains. (2010) (41)
- SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1 (2018) (40)
- The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. (2019) (38)
- Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer (2015) (38)
- Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer (2020) (37)
- An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer (2021) (36)
- Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer (2016) (34)
- Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. (2018) (34)
- Targeting Lyn regulates Snail family shuttling and inhibits metastasis (2017) (32)
- Targeting prostate cancer with HTI‐286, a synthetic analog of the marine sponge product hemiasterlin (2008) (32)
- Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. (2019) (30)
- The Multifaceted Roles of STAT 3 Signaling in the Progression of Prostate Cancer (2014) (30)
- Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer (2016) (28)
- Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition (2017) (28)
- Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer (2015) (28)
- The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer (2021) (27)
- Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma (2013) (27)
- BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer (2016) (26)
- The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer (2013) (25)
- Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer (2014) (25)
- Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. (2021) (24)
- Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer (2018) (22)
- Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer. (2017) (20)
- CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer (2021) (19)
- A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice (2015) (19)
- Patient-derived xenografts: A platform for accelerating translational research in prostate cancer (2017) (18)
- PEG10 is associated with treatment-induced neuroendocrine prostate cancer. (2019) (18)
- Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. (2012) (17)
- The Placental Gene PEG 10 Promotes Progression of Neuroendocrine Prostate Cancer Graphical (17)
- Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia (2017) (16)
- Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. (2018) (16)
- A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. (2015) (15)
- Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro (2014) (14)
- A broad-range of recombination cloning vectors in mycobacteria. (2009) (13)
- Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth (2014) (13)
- ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer (2022) (13)
- Clusterin Facilitates COMMD 1 and I-κ B Degradation to Enhance NF-κ B Activity in Prostate Cancer Cells (2010) (13)
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. (2008) (12)
- The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells (2016) (9)
- Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer (2020) (9)
- Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies (2021) (8)
- Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells (2020) (8)
- prognostic biomarkers (2017) (8)
- Abstract C89: Galeterone suppresses castration-resistant and enzalutamide-resistant prostate cancer growth in vitro. (2013) (8)
- Targeting androgen receptor signaling: a historical perspective. (2021) (6)
- Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence (2021) (6)
- Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer (2021) (6)
- Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer (2021) (6)
- Co‐targeting driver pathways in prostate cancer: two birds with one stone (2018) (6)
- An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model. (2011) (5)
- Abstract 3261: GRP78 regulates clusterin stability, retrotranslocation, and mitochondrial localization under ER stress in prostate cancer (2012) (5)
- Immunogenomic landscape of neuroendocrine small cell prostate cancer. (2019) (5)
- Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer. (2021) (4)
- Abstract 1295: First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer (2019) (4)
- The 5-Hydroxymethylcytosine Landscape of Prostate Cancer (2022) (4)
- MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER. (2014) (4)
- Clusterin Mediates TGF-b-Induced Epithelial-Mesenchymal TransitionandMetastasisviaTwist1inProstateCancer Cells (2012) (4)
- Rational cotargeting of Pim-1 and Akt in prostate cancer (2013) (3)
- Small Molecule Therapeutics Synergistic Targeting of PI 3 K / AKT Pathway and Androgen Receptor Axis Signi fi cantly Delays Castration-Resistant Prostate Cancer Progression In Vivo (2013) (3)
- Abstract 1595: Use of MDV3100 to establish androgen-receptor antagonist resistant LNCaP cells for modelling castrate-resistant progression (2011) (3)
- Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer (2013) (3)
- Abstract 676: Inhibition of FOXM1 targets both high and low PSA expressing prostate cancer cells resistant to Enzalutamide (2014) (3)
- Erratum: Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts (2015) (3)
- Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells (2019) (2)
- Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer. (2016) (2)
- Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer (2020) (2)
- SEMA 3 C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B 1 (2018) (2)
- Celebrating the 80th anniversary of hormone ablation for prostate cancer. (2021) (2)
- Neural Transcription Factors in Disease Progression. (2019) (2)
- Reduction in PD-L1 expression by STAT3 inhibition with GPA500 in enzalutamide-resistant prosate cancer. (2015) (2)
- Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity (2021) (2)
- 982 COMBINED TARGETING OF PI3K/AKT AND AR PATHWAY WITH AZD5363 AND ENZALUTAMIDE INDUCES ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF PROSTATE CANCER (2013) (2)
- 728 AZD5363, A NOVEL AKT INHIBITOR, DELAYS PROSTATE CANCER PROGRESSION (2011) (1)
- Abstract A39: A newly defined role of clusterin in the formation of exosomes derived from prostate cancer cells (2010) (1)
- CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. (2011) (1)
- ANTI-CANCER ACTIVITY OF A NOVEL SELECTIVE CYP 17 A 1 INHIBITOR IN PRE-CLINICAL MODELS OF CASTRATE RESISTANT PROSTATE CANCER (2014) (1)
- MP70-05 ANTI-CANCER ACTIVITY OF THE SELECTIVE CYP17A1 INHIBITOR, VT-464, IN PRE-CLINICAL MODELS OF CASTRATE RESISTANT PROSTATE CANCER (2014) (1)
- Therapeutic Discovery Cotargeting Stress-Activated Hsp 27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer (2012) (1)
- Molecular Mechanisms of Castrate Resistant Prostate Cancer (2013) (1)
- Abstract A087: Enzalutamide-induced hypoxia attenuates response and promotes resistance to enzalutamide in preclinical models of prostate cancer (2018) (1)
- MicroRNA-194 promotes lineage plasticity in advanced prostate cancer (2019) (1)
- Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticity (2021) (1)
- Abstract 732: Using functional and chemical genomics to identify mechanisms of Enzalutamide resistance in prostate cancer (2015) (1)
- Corrigendum re: "Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer" [Eur Urol 2014;66:145-55]. (2016) (1)
- Abstract 728: New derivative of galiellalactone inhibits the STAT3 activity and suppresses ENZ-resistant Prostate Cancerin vitro (2015) (1)
- 962 CLUSTERIN KNOCKDOWN ENHANCES ANTITUMOR ACTIVITY OF A NOVEL AKT INHIBITOR, AZD5363, THROUGH INHIBITION OF AUTOPHAGY IN PROSTATE CANCER (2012) (1)
- Identification and functional characterization of a long non-coding RNA driving hormone-independent prostate cancer progression. (2015) (1)
- Biologic consequences of androgen receptor (AR) activity in MDV3100-resistant LNCaP cells and dependence on AR full length. (2014) (1)
- Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer. (2014) (1)
- Abstract 5025: EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer (2017) (1)
- Abstract 3386: Mechanisms of resistance to enzalutamide in LNCaP models. (2013) (1)
- 255: Clusterin May Regulate NF-KB-Regulated Genes (2006) (0)
- Abstract B19: Induction of apoptosis and antitumor activity of the AKT inhibitor AZD5363 is enhanced by combination with hormonal therapies in preclinical models of prostate cancer (2012) (0)
- Abstract A19: Blocking autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363 (2012) (0)
- 550 HEAT SHOCK PROTEIN 27 INHIBITION ACTIVATES THE UNFOLD PROTEIN RESPONSE PATHWAY THROUGH INHIBITION OF PROTEASOME ACTIVITY IN PROSTATE CANCER (2010) (0)
- 613 IMMEDIATE, COMPARED TO DEFERRED, COMBINED ANDROGEN BLOCKADE PROLONGS TIME TO CASTRATE-RESISTANT LNCAP PROSTATE CANCER PROGRESSION IN VIVO (2011) (0)
- TARGETING THE CYTOPROTECTIVE CHAPERONE CLUSTERIN AS A STRATEGY TO INCREASE THE ANTICANCER ACTIVITY OF THE HSP90 INHIBITOR 17-ALLYLAMINO-DEMETHOXY GELDANAMYCIN (2008) (0)
- Preclinical Development Transcription Factor Stat 5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo (2011) (0)
- The Plasticity of Stem-Like States in Patient-Derived Tumor Xenografts (2017) (0)
- Abstract 3083: Selective inhibition of transcription factor BRN2 as a treatment strategy for Small Cell Prostate Cancer (2020) (0)
- Clusterin as a Target for Treatment of Castration-Resistant Prostate Cancer (2013) (0)
- TARGETING HSP27 ABROGATES IL-6 SIGNALLING PATHWAY AND PROLONGS TIME FOR CASTRATED RESISTANT PROSTATE CANCER (2009) (0)
- Abstract A029: Targeting neural transcription factor BRN2 in neuroendocrine prostate tumors (2018) (0)
- Abstract 623: CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer (2011) (0)
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer (2022) (0)
- MP37-12 INSULIN-LIKE GROWTH FACTOR-I INDUCES CLU EXPRESSION THROUGH TWIST1 TO PROMOTE PROSTATE CANCER GROWTH (2015) (0)
- 1126: HSP27 Controls Cell Growth and Apoptosis in LNCAP Cells by Regulating the Anti-Apoptotic Phosphoprotein, PEA-15 (2007) (0)
- Abstract 773: A heterochromatin gene signature unveils HP1α mediating neuroendocrine prostate cancer development and aggressiveness (2018) (0)
- UP-02.098 The Novel AKT-Inhibitor AZD5363 Abrogates Androgen-Receptor Signaling and Delays Hormone-Sensitive and Castration-Resistant Prostate Cancer Progression in vivo (2011) (0)
- 30PTreatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer (2017) (0)
- MP62-06 COMBINED AKT AND MEK PATHWAY BLOCKADE IN PRE-CLINICAL MODELS OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER (2016) (0)
- Abstract C91: Targeting enzalutamide resistance in prostate cancer. (2013) (0)
- Up-regulation of Hsp27 in prostate cancer cell lines induces resistance to various chemotherapeutics through Bax interaction (2008) (0)
- Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia (2017) (0)
- Abstract 4106: Lyn kinase promotes metastasis through EMT in cancers (2015) (0)
- Studies of Heat shock protein 27 Interactions (2014) (0)
- Hsp27 blockade selectively inhibits growth of tumors with an activated PI3K pathway by regulating Akt and PEA-15 (2008) (0)
- Abstract 4995: Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy (2018) (0)
- Translational Science (2018) (0)
- Abstract C128: Reprogramming transcription factors SOX2 and REST modulates SPINK1 expression in governing cellular plasticity in prostate cancer (2019) (0)
- Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy (2018) (0)
- Transition and Metastasis via Twist 1 in Prostate Cancer Cells Mesenchymal − Induced Epithelial − β Clusterin Mediates TGF-Updated (2012) (0)
- 235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model (2012) (0)
- Adaptive Stress Response and AR Stability Castrate-Resistant Prostate Cancer Progression by Inhibiting Cotargeting Androgen Receptor and Clusterin Delays (2013) (0)
- Abstract 14: Computer-aided discovery of small-molecule inhibitors targeting neural transcription factor BRN2 in neuroendocrine prostate tumors (2020) (0)
- Abstract 1682: Lyn drives cancer metastasis via post-translational regulation of SNAI proteins (2016) (0)
- INDUCTION OF HEAT SHOCK PROTEIN 25 ACTIVITY DURING INFLAMMATORY REACTIVE HYPERPLASIA OF THE PROSTATE (2009) (0)
- Abstract 281: Hsp27 is an essential effector of EGF-induced epithelial to mesenchymal transition in prostate cancer. (2013) (0)
- Cancer Therapy : Preclinical BlockedAutophagyUsingLysosomotropicAgentsSensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD 5363 (2013) (0)
- 481 CLUSTERIN IS A CRITICAL DOWNSTREAM MEDIATOR OF STRESS-INDUCED YB-1 TRANSACTIVATION IN PROSTATE CANCER (2012) (0)
- Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models (2021) (0)
- Abstract 1931: Targeting master neuronal transcription factor BRN2 in neuroendocrine prostate cancer (2018) (0)
- Abstract 4491: AZD5363, a novel Akt inhibitor, delays prostate cancer progression by inhibiting androgen-receptor activity (2011) (0)
- Pre-clinical rationale for combination PI3K and BRD4 inhibition in advanced prostate cancer. (2016) (0)
- Castration-Resistant Prostate Cancer (2018) (0)
- Abstract 3421: Twist1 and clusterin regulate epithelial-mesenchymal transition (2011) (0)
- MP24-04 CO-TARGETING CLUSTERIN AND THE ANDROGEN RECEPTOR WITH OGX-011 AND AN AR ANTISENSE SYNERGISTICALLY ENHANCES ACTIVITY OF ENZALUTAMIDE-RESISTANT PROSTATE CANCER (2014) (0)
- 615 HSP27 INHIBITION ACTIVATES THE UNFOLD PROTEIN RESPONSE AND AUTOPHAGY PATHWAY THROUGH INHIBITION OF PROTEASOME ACTIVITY IN PROSTATE CANCER (2011) (0)
- 1293 A NOVEL ANTI-ANDROGEN ARD1 DOWN-REGULATES ANDROGEN RECEPTOR LEVELS AND ACTIVITY AND SUPPRESSES PROSTATE CANCER LNCAP CELL GROWTH IN VITRO AND IN VIVO (2010) (0)
- Abstract 4512: The novel HSP90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth (2010) (0)
- Cellular plasticity and neuroendocrine phenotypes in prostate cancer (2023) (0)
- Abstract B173: Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2 (2015) (0)
- Abstract IA28: Targeting stress-induced molecular chaperones CLU and Hsp27 to inhibit EMT and metastases (2013) (0)
- Abstract 4730: ASCL1 activates neuronal stem cell-like lineage programming through the remodeling of the chromatin landscape in prostate cancer (2023) (0)
- 234 TARGETING STAT5 DEGRADES ANDROGEN RECEPTOR VIA THE PROTEASOME AND PROLONGS TIME TO TUMOR PROGRESSION POST CASTRATION IN VIVO (2010) (0)
- Co-targeting Adaptive Survival Pathways (2014) (0)
- PD32-07 GALETERONE SHOWS ANTI-TUMOR ACTIVITY IN MULTIPLE PRE-CLINICAL MODELS THAT EXPRESS ANDROGEN RECEPTOR SPLICE VARIANTS, SUPPORTING CORRELATIVE PATIENT DATA SEEN IN ARMOR2 (2016) (0)
- Beyond expression: role of phosphorylated residues of EZH2 in lineage plasticity in prostate cancer. (2023) (0)
- Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. (2013) (0)
- 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation (2016) (0)
- Abstract 4545: Lyn tyrosine kinase regulates androgen receptor expression and activity in prostate cancer (2011) (0)
- Targeting Hsp27 for the treatment of castrate-resistant prostate cancer (2011) (0)
- 972 a Novel Antiandrogen Pf-05234848 Suppresses Castration-Resistant and Mdv-3100-Resistant Prostate Cancer Growth in Vitro and in Vivo (2012) (0)
- MP52-08 TARGETING IGFBP-2 AND IGFBP-5 IN CASTRATION AND ENZALUTAMIDE RESISTANT PROSTATE CANCER (2014) (0)
- 546 ANDROGEN RECEPTOR ACTIVATION BY THE FER KINASE IN PROSTATE CANCER (2010) (0)
- PD32-01 PRE-CLINICAL RATIONALE FOR COMBINATION PI3K AND BRD4 INHIBITION IN ADVANCED PROSTATE CANCER (2016) (0)
- 321 ANTISENSE INHIBITOR TARGETING FULL LENGTH ANDROGEN RECEPTOR AND ITS SPLICE VARIANTS SUPPRESSES MDV3100 RESISTANT PROSTATE CANCER CELL GROWTH (2013) (0)
- 146: Clusterin is a Ubiquitin Binding Protein Involved in Murr1 and 1-KB Proteasomal Degradation to Confer Cell Survival in Prostate Cancer (2007) (0)
- 1298 THE NOVEL HSP90 INHIBITOR, PF-04929113, INHIBITS AR ACTIVITY AND OSTEOCLASTOGENESIS AND DELAYS CASTRATE RESISTANT LNCAP PROSTATE CANCER TUMOR GROWTH (2010) (0)
- 125 CLUSTERIN ANTISENSE INHIBITOR OGX-011 SYNERGIZES ACTIVITY OF SECOND GENERATION ANTI-ANDROGEN, MDV3100, IN CASTRATE RESISTANT PROSTATE CANCER MODEL (2011) (0)
- MP20-07 NPTX1 IS A NOVEL SERUM BIOMARKER INDUCED BY ARPI TREATED PROSTATE CANCER AND ENRICHED IN LINEAGE PLASTICITY WITH BRN2 HIGH (2023) (0)
- Abstract 4956: Hsp27 negatively affects Hippo tumor suppressor pathway to regulate cell survival in cancer (2015) (0)
- Predictive and prognostic biomarkers for next-generation hormonal agents in castration resistant prostate cancer (2015) (0)
- Molecular and Cellular Pathobiology Clusterin Mediates TGF-b – Induced Epithelial – Mesenchymal Transition andMetastasis via Twist 1 in Prostate Cancer Cells (2012) (0)
- Abstract 1796: Novel triazole nucleoside inhibits heat shock factor 1 and androgen receptor to fight against prostate cancer (2014) (0)
- Abstract C25: Hsp27 is required for EGF-induced epithelial to mesenchymal transition in prostate cancer (2013) (0)
- 1279 CLU INHIBITION USING OGX-011 IS A NEW ADJUVANT THERAPEUTIC STRATEGY FOR HSP90 INHIBITION IN PROSTATE CANCER (2011) (0)
- Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models (2021) (0)
- Treatment resistance in prostate cancer: Rationale of combination therapy (85.2) (2014) (0)
- Discovery and characterization of a first-in-field transcription factor BRN2 inhibitor for the treatment of neuroendocrine prostate cancer (2022) (0)
- Abstract 2074: Hsp27 inhibition activates the unfold protein response and autophagy pathway through inhibition of proteasome activity in prostate cancer (2011) (0)
- HSP27 PROMOTES IGF-1 SURVIVAL SIGNALING IN PROSTATE CANCER VIA P90RSK-DEPENDENT PHOSPHORYLATION AND INACTIVATION OF BAD (2009) (0)
- Rationale targeting cell plasticity in treatment resistant prostate cancer (2018) (0)
- Abstract 3441: A multivalent peptoid conjugate that inhibits therapy-resistant prostate cancer cell proliferation by modulating androgen receptor transcriptional activity (2023) (0)
- 245 Downregulation of Hsp27 using OGX-427 induces ER stress and potentiates Hsp90 inhibitors to delay castrate resistant prostate cancer (2012) (0)
- Targeting Neuronal Transcription Factor BRN2 in Neuroendocrine Tumors (2019) (0)
- HSP27 BLOCKADE SELECTIVELY INHIBITS GROWTH OF PTEN DEFICIENT TUMORS BY REGULATING PEA-15 ACTIVITY IN AN AKT DEPENDENT MANNER (2009) (0)
- Abstract 3189: Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer (2017) (0)
- Abstract CN06-01: Lineage plasticity and the neuroendocrine phenotype as a resistance mechanism in prostate cancer (2019) (0)
- Abstract 4150: Exploration of the role of Hsps in exosome derived from prostate cancer cells (2010) (0)
- Abstract 3342: Galiellalactone derivative targets stem cell population in ENZ-resistant prostate cancer through inhibition of STAT3 (2016) (0)
- Abstract 1241: In vivo analysis of the role of Lyn tyrosine kinase in castrate-resistant LNCaP xenograft tumor growth (2012) (0)
- 812: Androgen and HSP27 Cooperatively Interact to Facilitate Genomic and Non-Genomic Activity of the Androgen Receptor to Enhance Prostate Cancer Survival (2006) (0)
- Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer (2014) (0)
- ONECUT2 is a driver of neuroendocrine prostate cancer (2019) (0)
- Abstract 4062: Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis. (2013) (0)
- Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer (2018) (0)
This paper list is powered by the following services:
Other Resources About Amina Zoubeidi
What Schools Are Affiliated With Amina Zoubeidi?
Amina Zoubeidi is affiliated with the following schools:
